All News
Filter News
Found 4,283 articles
-
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
3/5/2024
Akari Therapeutics, Plc and Peak Bio Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction.
-
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
3/5/2024
ALX Oncology Holdings Inc. announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research Annual Meeting, which will be held in San Diego from April 5-10, 2024.
-
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
3/5/2024
Vincerx Pharma, Inc. announced it will present three posters at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, CA, from April 5 – 10, 2024.
-
MBrace Therapeutics Appoints Steve Alley as Chief Scientific Officer
3/5/2024
MBrace™ Therapeutics, Inc. today announced the appointment of Steve Alley, Ph.D., as chief scientific officer.
-
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
3/5/2024
Zymeworks Inc. announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024.
-
Shasqi to Present New Data at 2024 World ADC London Conference
3/5/2024
Shasqi, Inc. announced that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 14th Annual World ADC Conference in London, United Kingdom on Tuesday March 12th at 11:00am GMT.
-
Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024
3/5/2024
Tubulis announced that two abstracts with comprehensive preclinical data on their next-generation antibody-drug conjugate candidates TUB-030 and TUB-040, have been accepted for poster presentations at the Annual Meeting of the American Association for Cancer Research, taking place April 5-10, 2024 in San Diego.
-
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
3/5/2024
Lantern Pharma will present virtually on Thursday, March 7th at 2 pm Eastern.
-
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
3/5/2024
Pyxis Oncology, Inc. (Nasdaq: PYXS) announced today that the company will present new preclinical data in four posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held from April 5 to 10, 2024.
-
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
3/5/2024
Elevation Oncology, Inc. (Nasdaq: ELEV) today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
-
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
3/5/2024
ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024.
-
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
3/5/2024
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that four preclinical abstracts have been selected as poster presentations at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024).
-
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
3/4/2024
Elevation Oncology, Inc. announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors.
-
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024
3/4/2024
Lantern Pharma's A.I. Platform, RADR ® Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines.
-
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology
3/4/2024
Defence Therapeutics Inc. is pleased to announce the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office (USPTO), broadly covering its breakthrough AccuTOX® technology.
-
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
3/4/2024
CytomX Therapeutics, Inc. today announced that it will report full year 2023 financial results on Monday, March 11, 2024, after the close of U.S. markets.
-
Antibody-drug conjugates are a breakthrough in targeted cancer therapy and will continue to attract big pharma investment over the next few years, finds a new report from market intelligence firm Evaluate.
-
Retaining the full rights to Trodelvy, Gilead now has access to $210 million in financing from venture capital firm Abingworth to help push the antibody-drug conjugate into non-small cell lung cancer studies.
-
ImmunoScape Leadership to Present at Upcoming March 2024 Industry Conferences
3/1/2024
ImmunoScape, a biotechnology company focused on next-generation T Cell receptor -based immunotherapies, announced that members of its executive team will present at two upcoming conferences, BioCentury-BayHelix East-West Summit 2024 and The State of Precision Medicine 2024.
-
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
3/1/2024
Defence Therapeutics Inc. is pleased to announce the publication of a peer-reviewed study on the anticancer properties of its dual Accum®-E7 vaccine, one of Defence's experimental product designed to treat established cervical cancer.